FDA OKs new use for BladderChek test:
This article was originally published in Clinica
Matritech has gained US approval to expand the use of its rapid, doctor's office bladder cancer test to help in the diagnosis of the disease. The NMP22 BladderChek test, previously cleared for monitoring patients already diagnosed with the disease, detects a bladder cancer nuclear matrix protein in urine. Matritech, of Newton, Massachusetts, notes that according to the American Cancer Society, 41,500 new cases of bladder cancer are diagnosed in men each year. The BladderChek test will be distributed in the US by Princeton, New Jersey-based, Cytogen.